PurMinds NeuroPharma
This neuro-medicine development company is creating non-hallucinogenic neuroplastogens that act as serotonin 5-HT2AC receptor partial agonists to enhance neuroplasticity in patients with neurological and psychiatric disorders. Their pipeline also includes selective HDAC6 inhibitors, targeting significant unmet needs in therapeutic options for these conditions.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$14.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- This neuro-medicine development company is creating non-hallucinogenic neuroplastogens that act as serotonin 5-HT2AC receptor partial agonists to enhance neuroplasticity in patients with neurological and psychiatric disorders. Their pipeline also includes selective HDAC6 inhibitors, targeting significant unmet needs in therapeutic options for these conditions.